2-Furancarboxamide,N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-

The IUPAC name of Alfuzosin is N-[3-[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]propyl]oxolane-2-carboxamide. With the CAS registry number 81403-80-7, it is also named as 2-Furancarboxamide,N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl) methylamino]propyl]tetrahydro-. The product's categories are APIs; Adrenoceptor, and the other registry numbers are 128707-53-9;  86163-78-2. In addition, its molecular formula is C₁₉H₂₇N₅O₄ and molecular weight is 389.45.

The other characteristics of Alfuzosin can be summarized as: (1)ACD/LogP: -1.00; (2)# of Rule of 5 Violations: 0; (3)ACD/LogD (pH 5.5): -3.43; (4)ACD/LogD (pH 7.4): -2.33; (5)ACD/BCF (pH 5.5): 1; (6)ACD/BCF (pH 7.4): 1; (7)ACD/KOC (pH 5.5): 1; (8)ACD/KOC (pH 7.4): 1; (9)#H bond acceptors: 9; (10)#H bond donors: 3; (11)#Freely Rotating Bonds: 8; (12)Polar Surface Area: 80.26 Å²; (13)Index of Refraction: 1.62; (14)Molar Refractivity: 107.62 cm³; (15)Molar Volume: 306 cm³; (16)Polarizability: 42.66×10^-24cm³; (17)Surface Tension: 60.6 dyne/cm; (18)Density: 1.272 g/cm³.

Uses of this chemical: it is an α1 receptor antagonist which is used to treat benign prostatic hyperplasia (BPH). It works by relaxing the muscles in the prostate and bladder neck, making it easier to urinate. Moreover, it should be used with caution in patients with severe renal insufficiency.

People can use the following data to convert to the molecule structure.
(1)SMILES: O=C(NCCCN(c2nc1cc(OC)c(OC)cc1c(n2)N)C)C3OCCC3
(2)InChI: InChI=1/C19H27N5O4/c1-24(8-5-7-21-18(25)14-6-4-9-28-14)19-22-13-11-16(27-3)15(26-2)10-12(13)17(20)23-19/h10-11,14H,4-9H2,1-3H3,(H,21,25)(H2,20,22,23)
(3)InChIKey: WNMJYKCGWZFFKR-UHFFFAOYAD
(4)Std. InChI: InChI=1S/C19H27N5O4/c1-24(8-5-7-21-18(25)14-6-4-9-28-14)19-22-13-11-16(27-3)15(26-2)10-12(13)17(20)23-19/h10-11,14H,4-9H2,1-3H3,(H,21,25)(H2,20,22,23)
(5)Std. InChIKey: WNMJYKCGWZFFKR-UHFFFAOYSA-N